Cross-Intolerance with Dasatinib among Imatinib-Intolerant Patients with Chronic Phase Chronic Myeloid Leukemia.
Clinical Lymphoma, Myeloma and Leukemia.
Times cited: 4
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median follow-up.
Times cited: 134